Drug manufacturers’ decisions to impose conditions on 340B pricing when covered entities use contract pharmacies “need to be addressed moving forward,” U.S. Rep. Debbie Dingell (D-Mich.) said last week during an Energy & Commerce (E&C) health subcommittee hearing last week.
Read More »Articles by : Tom Mirga, Editor at Large
For the fourth time this year, drug manufacturer Lilly has announced refunds for overcharges on 340B-purchased drugs during 2019.
The U.S. Health Resources and Services Administration (HRSA) posted the notice, dated May 27, on the Office of Pharmacy Affairs website
Read More »Drug manufacturers Novo Nordisk and Sanofi last month urged a federal appeals court to reverse a district judge’s ruling that the companies’ conditions on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.
Meanwhile, the federal government
Read More »Prescription drugs sales at 340B prices were $38.8 billion in 2020, “more than three times the level of 340B sales compared to just five years prior,” new drug industry funded research shows.
Total sales would have been $93.6 billion if
Read More »Breaking News
In Important Ruling, Federal Appeals Court Says Health Center May Challenge 340B Patient Definition’s Legality
A federal appeals court ruled unanimously this morning that a South Carolina health center has the right to challenge the legality of the government’s 340B patient definition in a lower federal court. The case ultimately could have profound implications for
Read More »Bausch Health this afternoon became the 18th drug manufacturer to impose conditions on 340B pricing when covered entities use contract pharmacies. The restrictions apply to all entities; there is no exemption for federal grantees.
According to Bausch’s announcement, effective Aug.
Read More »The U.S. House Appropriations Committee said this week it is concerned about the growing number of drug manufacturers “that curtail the use of 340B drugs in contract pharmacies.” It encouraged the U.S. Health Resources and Services Administration to use “any
Read More »Drug manufacturer UCB says it is reviewing Monday’s letter from the U.S. Health Resources and Services Administration telling the company its restrictions on 340B pricing to covered entities that use contract pharmacies break federal law and must end immediately.
“At
Read More »A bill in California to prohibit drug manufacturer conditions on 340B pricing and pharmacy benefit manager discrimination against 340B covered entities died in a state Assembly committee on Tuesday.
The state Senate voted 24-9 to pass the bill, SB-939, on
Read More »The American Hospital Association wants to discuss with U.S. Health and Human Services Secretary Xavier Becerra how 340B hospitals should be promptly repaid “for all of the years (2018-2022) in which the Centers for Medicare & Medicaid Services (CMS) illegally
Read More »